Skip to content

Study on the intervention of people with dampness syndrome hyperuricemia

Study on the intervention of people with dampness syndrome hyperuricemia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000058
Enrollment
Unknown
Registered
2024-05-09
Start date
2023-04-01
Completion date
Unknown
Last updated
2024-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricaemia

Interventions

treatment group:Yinling Qushi granule
control group:Yinling Qushi granule simulator

Sponsors

Guangdong Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: People aged between 18 and 75 years (including 18 and 75 years) Diagnosis of hyperuricemia Diagnosis of dampness syndrome Informed consent is signed by participants.

Exclusion criteria

Exclusion criteria: 1.People with secondary hyperuricemia, such as hyperuricemia secondary to malignant tumors, blood diseases, kidney diseases, chronic poisoning, etc; 2.People who have a history of alcoholism and have not abstained in the last 3 months 3.one or more previous episodes of gouty arthritis; 4.In the past 4 weeks, the subjects have taken uric acid lowering drugs, or drugs that can cause increased blood uric acid(1) Antituberculosis drugs: pyrazinamide/ethambutol/isoniazid, (2) low-dose aspirin, (4) loop diuretics and thiazide diuretics and antihypertensive drugs containing diuretics, (5) niacin, (6) high-dose vitamin C, (7) tumor chemotherapeutics, (8) cyclosporine; 5.Pregnancy and lactation, or the possibility of pregnancy and failed to take effective contraceptive measures; 6.Glutamic pyruvic transaminase or glutamic oxalacetic transaminase or creatinine is 2 times or more than the normal value; 7.Subjects with severe organic diseases, mental disorders or other reasons can not cooperate with treatment; 8.Allergic or ineffective to the test drug ingredient.

Design outcomes

Primary

MeasureTime frame
Score of dampness syndrome;Blood uric acid drop number;

Secondary

MeasureTime frame
Incidence of hyperlipidemia;Cardiovascular event incidence;Joint ultrasound;hsCRP;TNF-a;Incidence of hyperlipidemia;IL-6;Incidence of gout;Urinary beta-2 microglobulin;glomerular filtration rate;Blood and urine metabolites;Incidence of diabetes;coating on the tongue;Fecal flora;

Countries

China

Contacts

Public ContactXiaohong He

Guangdong Hospital of Traditional Chinese Medicine

wdtsxh521@126.com13660581225

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026